Hot on the heels of its up to $815 million oncology-related deal with Boehringer Ingelheim (The Pharma Letter January 6), US drug discovery biotech firm FORMA Therapeutics has signed an exclusive alliance with Janssen Biotech, part of US health care giant Johnson & Johnson (NYSE: JNJ), in which the two companies will collaborate on the discovery, development and commercialization of novel small-molecule drug candidates that target tumor metabolism mechanisms.
Under the terms of the research collaboration and license option agreement, FORMA will discover and develop drugs against a panel of tumor metabolism targets. FORMA may receive project and milestone funding over several years of up to $700 million if development, regulatory and commercialization milestones are achieved for drug candidates successfully launched through the collaboration.
FORMA could have rights to one program for North America
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze